Anixa Biosciences Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Anixa Biosciences, Inc. will hold its 2024 Virtual Annual Meeting of Stockholders on March 21, 2024, to elect directors, approve executive compensation, and ratify auditor appointments.</b>

AI Summary

Anixa Biosciences Inc (ANIX) filed a Proxy Statement (DEF 14A) with the SEC on February 8, 2024. The 2024 Annual Meeting of Stockholders for Anixa Biosciences, Inc. will be held virtually on March 21, 2024, at 10:00 a.m. Pacific Time. The meeting agenda includes the election of four director nominees: Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. Stockholders will vote on a non-binding, advisory basis for the compensation of named executive officers. The appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending October 31, 2024, will be ratified. The Board of Directors unanimously recommends voting for the election of each director nominee.

Why It Matters

For investors and stakeholders tracking Anixa Biosciences Inc, this filing contains several important signals. The election of directors and ratification of the auditor are standard corporate governance procedures crucial for the company's ongoing operations and investor confidence. The advisory vote on executive compensation allows shareholders to voice their opinion on the company's pay practices for its top executives, influencing future compensation strategies.

Risk Assessment

Risk Level: — Anixa Biosciences Inc shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.

Analyst Insight

Stockholders should review the director nominees and executive compensation proposals before the March 21, 2024 meeting.

Key Numbers

• 2024-03-21 — Virtual Meeting Date (2024 Annual Meeting of Stockholders)
• 10:00 a.m. Pacific Time — Virtual Meeting Time (2024 Annual Meeting of Stockholders)
• 2025-10-31 — Director Term Expiration (Term expires at the 2025 Annual Meeting of Stockholders)
• 2024-10-31 — Fiscal Year End (Fiscal year ending October 31, 2024)

Key Players & Entities

• Anixa Biosciences, Inc. (company) — Registrant
• Dr. Amit Kumar (person) — Director Nominee
• Dr. Arnold Baskies (person) — Director Nominee
• Emily Gottschalk (person) — Director Nominee
• Lewis H. Titterton, Jr. (person) — Director Nominee
• Haskell & White LLP (company) — Independent registered public accounting firm

FAQ

Industry Context

Anixa Biosciences, Inc. is a biotechnology company focused on developing treatments for cancer. This filing is a standard proxy statement for its annual shareholder meeting.

Regulatory Implications

The filing is made under Schedule 14A of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.

What Investors Should Do

1. Review the qualifications of the director nominees before voting.
2. Consider the advisory vote on executive compensation.
3. Confirm the ratification of Haskell & White LLP as the independent auditor.

Key Dates

• 2024-03-21: 2024 Annual Meeting of Stockholders — To elect directors, approve executive compensation, and ratify auditor appointment.

Year-Over-Year Comparison

This is a definitive proxy statement filed on February 8, 2024, for the upcoming annual meeting. No prior filing details for this specific meeting are provided in this document.

Key Financial Figures

• $0.01 — d shares of our common stock, par value $0.01 per share (&ldquo; Common Stock &rdquo;

Filing Documents

• formdef14a.htm (DEF 14A) — 444KB
• chart_001.jpg (GRAPHIC) — 60KB
• chart_002.jpg (GRAPHIC) — 60KB
• 0001493152-24-005470.txt (&nbsp;) — 611KB

From the Filing

DEF 14A 1 formdef14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. 1) Title of each class of securities to which transaction applies: 2) Aggregate number of securities to which transaction applies: 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11: 4) Proposed maximum aggregate value of transaction: 5) Total fee paid: Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: ANIXA BIOSCIENCES, INC. 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 February 8, 2024 To the Stockholders of Anixa Biosciences, Inc.: You are cordially invited to attend the 2024 Annual Meeting of Stockholders (the &ldquo; Virtual Meeting &rdquo;) of Anixa Biosciences, Inc. (the &ldquo; Company &rdquo;) to be held on a virtual basis on Thursday, March 21, 2024 at 10:00 a.m. Pacific Time, for the following purposes: 1. To elect Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. as directors (the &ldquo; Director Nominees &rdquo;) to serve on the Company&rsquo;s Board of Directors (the &ldquo; Board &rdquo;) for a one-year term that expires at the 2025 Annual Meeting of Stockholders, or until their successors are elected and qualified; 2. To approve on a non-binding, advisory basis the compensation of our named executive officers; 3. To ratify the appointment by the Board of Haskell & White LLP as the Company&rsquo;s independent registered public accounting firm for the fiscal year ending October 31, 2024; and 4. To transact such other business as may properly come before the Virtual Meeting or any adjournment thereof. THE BOARD UNANIMOUSLY RECOMMENDS A VOTE FOR THE ELECTION OF EACH OF THE DIRECTOR NOMINEES, A vote FOR the approval on a non-binding, advisory basis, of the compensation of our named executive officers, AND A VOTE FOR THE RATIFICATION OF THE APPOINTMENT OF THE COMPANY&rsquo;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING OCTOBER 31, 2024 . The Board has fixed the close of business on January 25, 2024 as the record date (the &ldquo; Record Date &rdquo;) for the determination of stockholders entitled to notice of, and to vote at, the Virtual Meeting or any postponement or adjournment thereof. Accordingly, only stockholders of record at the close of business on the Record Date are entitled to notice of, and shall be entitled to vote at, the Virtual Meeting or any postponement or adjournment thereof. Your vote is important. You are requested to carefully read the Proxy Statement and accompanying Notice of Annual Meeting for a more complete Sincerely yours, /s/ Dr. Amit Kumar Dr. Amit Kumar Chairman and Chief Executive Officer Anixa Biosciences, Inc. IMPORTANT WHETHER OR NOT YOU EXPECT TO ATTEND THE VIRTUAL MEETING, please read the proxy statement and promptly vote your proxy VIA the internet, by telephone or, if you received a printed form of proxy in the mail, by completing, dating, signing and returning the enclosed proxy IN ORDER TO ASSURE REPRESENTATION OF YOUR SHARES AT THE VIRTUAL MEETING. YOUR PROXY, GIVEN THROUGH THE RETURN OF THE PROXY CARD, MAY BE REVOKED PRIOR TO ITS EXERCISE BY FILING WITH OUR CORPORATE SECRETARY PRIOR TO THE VIRTUAL MEETING A WRITTEN NOTICE OF REVOCATION OR A DULY EXECUTED PROXY BEARING A LATER DATE, OR BY ATTENDING THE VIRTUAL MEETING AND VOTING. IF YOU HAVE ALREADY VOTED OR DELIVERED YOUR PROXY FOR THE VIRTUAL MEETING, YOUR VOTE WILL BE COUNTED, AND YOU DO NOT HAVE TO VOTE YOUR SHARES AGAIN. IF YOU WISH TO CHANGE YOUR VOTE, YOU SHOULD REVOTE YOUR SHARES. THE PROXY STATEMENT, OUR FORM OF PROXY CARD, AND OUR ANNUAL REPORT ON FORM 10-K FOR THE FISCAL YEAR ENDED OCTOBER 31, 2023 ARE AVAILABLE ON THE INTERNET AT http://ir.ANIXA.com/sec-fil

View Full Filing

View this DEF 14A filing on SEC EDGAR